Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Best of ASCO® Miami 2016 /
Review of olaparib for ovarian cancer

8th - 10th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.07.16
Views: 2048

Dr Michel Vulfovich - Memorial Cancer Institute, Hollywood, Florida, USA

 Dr Vulfovich speaks with ecancertv at the Best of ASCO 2016 about novel treatments for ovarian cancer.

Using BRCA mutations as a marker, he describes the significance of PARP inhibitor treatment on survival.

For the initial announcement of results from olaparib in ovarian cancer, you can watch an interview with Dr Jonathan Ledermann here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation